{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:42:05Z","timestamp":1793457725227,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004493","name":"International Atomic Energy Agency","doi-asserted-by":"publisher","award":["26344"],"award-info":[{"award-number":["26344"]}],"id":[{"id":"10.13039\/501100004493","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.nucmedbio.2025.109032","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:34:00Z","timestamp":1749209640000},"page":"109032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Preclinical evaluation of [225Ac]Ac-PSMA-617 and in vivo effect comparison in combination with [177Lu]Lu-PSMA-617 for prostate cancer"],"prefix":"10.1016","volume":"146-147","author":[{"given":"E.","family":"Savio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Alfaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Falasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Urrutia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bentura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zirbesegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Arredondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Gambini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dapueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2025.109032_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.nucmedbio.2025.109032_bb0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11110560","article-title":"The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research","volume":"11","author":"Ruigrok","year":"2019","journal-title":"Pharmaceutics"},{"issue":"23","key":"10.1016\/j.nucmedbio.2025.109032_bb0020","doi-asserted-by":"crossref","first-page":"34930","DOI":"10.18632\/oncotarget.9004","article-title":"Heterogeneous PSMA expression on circulating tumour cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer","volume":"7","author":"Gorges","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.nucmedbio.2025.109032_bb0025","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","article-title":"Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoural PSMA heterogeneity","volume":"26","author":"Current","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2967\/jnumed.121.262413","article-title":"Prostate Cancer treatment: 177Lu-PSMA-617 considerations, concepts, and limitations","volume":"63","author":"Sartor","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2025.109032_bb0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","article-title":"Safety analyses of the phase 3 VISION trial of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate Cancer","volume":"85","author":"Chi","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2025.109032_bb0040","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186602","article-title":"Comparison of high- and low-LET RadiationInduced DNA double-Strand break processing in living cells","volume":"21","author":"Roobol","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.semnuclmed.2008.05.002","article-title":"Therapeutic radionuclides: biophysical and radiobiologic principles","volume":"38","author":"Kassis","year":"2008","journal-title":"Semin Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2025.109032_bb0055","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.7150\/thno.96403","article-title":"Actinium-225 targeted alpha particle therapy for prostate cancer","volume":"14","author":"Bidkar","year":"2024","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.nucmedbio.2025.109032_bb0060","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3390\/pharmaceutics14102166","article-title":"Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate Cancer","volume":"14","author":"Ling","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41181-018-0039-y","article-title":"Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform","volume":"3","author":"Giglio","year":"2018","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0070","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/mirt.galenos.2021.63308","article-title":"Relative efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in prostate cancer based on subcellular dosimetry","volume":"31","author":"Lee","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0080","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","article-title":"In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0090","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0095","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2025.109032_bb0100","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMATargeted \u03b1 radiation therapy of metastatic castration-resistant prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2025.109032_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:49:43Z","timestamp":1778575783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805125000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"alternative-id":["S0969805125000411"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109032","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of [225Ac]Ac-PSMA-617 and in vivo effect comparison in combination with [177Lu]Lu-PSMA-617 for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109032"}}